| [1] |
WU Z H, XIA F N, LIN R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021[J]. J Hematol Oncol, 2024, 17(1): 119.
|
| [2] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [3] |
文天夫, 李 川, 张晓赟, 等. “健康中国2030”肝癌5年生存率提高15%的关键[J]. 中国普外基础与临床杂志,2023, 30(11): 1281-1283.
|
| [4] |
DIAO X Y, GUO C, JIN Y K, et al. Cancer situation in China: an analysis based on the global epidemiological data released in 2024[J]. Cancer Commun (Lond), 2025, 45(2): 178-197.
|
| [5] |
ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-231.
|
| [6] |
IOANNOU G N. Epidemiology and risk-stratification of NAFLD-associated HCC[J]. J Hepatol, 2021, 75(6): 1476-1484.
|
| [7] |
CHOI J, LIM Y S. Genetic-based risk assessment for hepatocellular carcinoma in patients with hepatitis C: where do we stand?[J]. EBioMedicine, 2017, 15: 6-7.
|
| [8] |
CHEN Y, ZHAO L G, JUNG S Y, et al. Diabetes risk reduction diet and risk of liver cancer and chronic liver disease mortality: a prospective cohort study[J]. J Intern Med, 2024, 296(5): 410-421.
|
| [9] |
陈嘉慧, 王海博, 柯立鑫, 等. 1990年—2021年中国因非酒精性脂肪性肝炎所致肝癌的疾病负担分析与未来趋势预测研究[J]. 华西医学, 2025, 40(4): 546-553.
|
| [10] |
贾士杰, 张 彬, 刘领弟, 等. 1990—2019年中国乙型肝炎病毒相关肝癌发病及死亡趋势分析[J]. 中华肿瘤防治杂志, 2024, 31(8): 486-491.
|
| [11] |
LIN Y S, ZHENG L Y, FANG K L, et al. Proportion of liver cancer cases and deaths attributable to potentially modifiable risk factors in China[J]. Int J Epidemiol, 2023, 52(6): 1805-1814.
|
| [12] |
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2133-2161.
|
| [13] |
LV B, LAN J X, SI Y F, et al. Epidemiological trends of subarachnoid hemorrhage at global, regional, and national level: a trend analysis study from 1990 to 2021[J]. Mil Med Res, 2024, 11(1): 46.
|
| [14] |
KUANG Z Y, WANG J X, LIU K X, et al. Global, regional, and national burden of tracheal, bronchus, and lung cancer and its risk factors from 1990 to 2021: findings from the global burden of disease study 2021[J]. EClinicalMedicine, 2024, 75: 102804.
|
| [15] |
CAO G Y, LIU J, LIU M. Global, regional, and national trends in incidence and mortality of primary liver cancer and its underlying etiologies from 1990 to 2019: results from the global burden of disease study 2019[J]. J Epidemiol Glob Health, 2023, 13(2): 344-360.
|
| [16] |
CUI F Q, ZHUANG H. Progress in prevention and control of viral hepatitis since the establishing of the People’s Republic of China[J]. Zhonghua Gan Zang Bing Za Zhi, 2021, 29(8): 725-731.
|
| [17] |
NING H B, LI K, SHANG J. Immunotherapy the road of hope for patients with advanced liver cancer in the new era[J]. Zhonghua Gan Zang Bing Za Zhi, 2021, 29(4): 301-303.
|
| [18] |
LI M, WANG Z Q, ZHANG L, et al. Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990-2016: findings from the global burden of disease study 2016[J]. Biomed Environ Sci, 2020, 33(1): 1-10.
|
| [19] |
ZHU S, CHEN S T, JIN Y Y, et al. Analysis and prediction of disease burden of cirrhosis and other chronic liver diseases due to alcohol use in China from 1990 to 2030[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2024, 45(2): 185-191.
|
| [20] |
YU S X, WANG H W, HU T Y, et al. Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019: an age-period-cohort analysis[J]. Sci Prog, 2021, 104(2): 368504211018081.
|
| [21] |
YUE T T, XU M, CAI T, et al. Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period[J]. Front Public Health, 2022, 10: 956712.
|
| [22] |
CAO M M, DING C, XIA C F, et al. Attributable deaths of liver cancer in China[J]. Chin J Cancer Res, 2021, 33(4): 480-489.
|
| [23] |
刘芷希, 汪业胜, 王伟炳. 中国1990—2017年乙型肝炎疫情的变化趋势研究[J]. 中华流行病学杂志, 2021, 42(4): 613-619.
|
| [24] |
SUN L C, YANG Y, LI Y, et al. The past, present, and future of liver cancer research in China[J]. Cancer Lett, 2023, 574: 216334.
|
| [25] |
PANG Q, QU K, ZHANG J Y, et al. Cigarette smoking increases the risk of mortality from liver cancer: a clinical-based cohort and meta-analysis[J]. J Gastroenterol Hepatol, 2015, 30(10): 1450-1460.
|
| [26] |
赫 捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022, 北京)[J]. 中国肿瘤, 2022, 31(8): 587-631.
|